Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data
Yuntae Kim,1,2 Shun Yamamoto,1 Ken Kato1 1Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; 2Department of Gastroenterology, St. Luke International Hospital, Tokyo, JapanCorrespondence: Ken Kato, Department of Head and Neck, Esophageal Medical O...
Main Authors: | Kim Y, Yamamoto S, Kato K |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-05-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/profile-of-nivolumab-in-the-treatment-of-resected-esophageal-squamous--peer-reviewed-fulltext-article-CMAR |
Similar Items
-
Successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapy
by: Katsuhisa Sekido, et al.
Published: (2023-12-01) -
Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma
by: Manato Ohsawa, et al.
Published: (2023-04-01) -
Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma
by: Shixian Liu, et al.
Published: (2022-07-01) -
Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
by: Huilai Lv, et al.
Published: (2022-04-01) -
A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy
by: Alice Horisberger, et al.
Published: (2018-12-01)